Why the study?
Does rivaroxaban improve left atrial appendage thrombus resolution in a patient with atrial fibrillation and thrombophilia who failed warfarin therapy?
Does rivaroxaban improve left atrial appendage thrombus resolution in a patient with atrial fibrillation and thrombophilia who failed warfarin therapy?
Rivaroxaban may be a safe and effective alternative for resolving left atrial appendage thrombi in patients with atrial fibrillation and inherited thrombophilias who experience treatment failure with warfarin.
May support rivaroxaban for LAA thrombus resolution after warfarin failure in thrombophilia; hypothesis-generating, requiring prospective confirmation.
BACKGROUND: Atrial fibrillation is the most common cardiac arrhythmia. It is responsible for up to 20% of all ischemic strokes. Rate control and anticoagulation are crucial for atrial fibrillation management and stroke prevention. CASE PRESENTATION: We present the case of an 84-year-old Italian woman with a left atrial appendage thrombus that developed despite her use of anticoagulant therapy with warfarin for a previous pulmonary embolism. She had atrial fibrillation and heterozygosity for both factor V Leiden and methylenetetrahydrofolate reductase C677T mutation, thus creating resistance to activated protein C. Anticoagulant therapy was switched to heparin for 1 week and then to rivaroxaban. After 3 months of rivaroxaban use, the thrombus disappeared. CONCLUSIONS: This case raises the issue of the ineffectiveness of warfarin therapy in complex cases involving particular thrombophilic conditions and the possibility of using rivaroxaban as a safe and effective alternative.
No takes yet. Share an insight, caveat, or question.
Scarano et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: